Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice

Cancer Research

Volumn 63, Issue 5, 2003, Pages 895-901

  Yamada, Tesshi ^a   Mori, Yasuharu ^a   Hayashi, Reiko ^a   Takada, Mizuho ^a   Ino, Yoshinori ^a   Naishiro, Yasuyoshi ^a   Kondo, Tadashi ^a   Hirohashi, Setsuo ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GENE PRODUCT; MULTIDRUG RESISTANCE PROTEIN 1; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GASTROINTESTINAL POLYPOSIS; GENE; GENE REPRESSION; GENE TARGETING; MALE; MDR1 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION;

ANIMALS; BETA CATENIN; CELL DIVISION; CYCLOSPORINE; CYTOSKELETAL PROTEINS; GENE TRANSFER TECHNIQUES; GENES, APC; GENES, MDR; GERM-LINE MUTATION; INTESTINAL POLYPS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-GLYCOPROTEIN; RATS; TRANS-ACTIVATORS; VERAPAMIL;

EID: 0037373889     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal Cancer. Cell, 87: 159-170, 1996.
2. Wong, N. A., and Pignatelli, M. Beta-catenin: a linchpin in colorectal carcinogenesis? Am. J. Pathol., 160: 389-401, 2002.
3. Koh, T. J., Bulitta, C. J., Fleming, J. V., Dockray, G. J., Varro, A., and Wang, T. C. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J. Clin. Investig., 106: 533-539, 2000.
4. Fujita, M., Furukawa, Y., Tsunoda, T., Tanaka, T., Ogawa, M., and Nakamura, Y. Up-regulation of the ectodermal-neural cortex I (ENC1) gene, a downstream target of the β-catenin/t-cell factor complex, in colorectal carcinomas. Cancer Res., 61: 7722-7726, 2001.
5. Hlubek, F., Jung, A., Kotzor, N., Kirchner, T., and Brabletz, T. Expression of the invasion factor laminin γ2 in colorectal carcinomas is regulated by β-catenin. Cancer Res., 61: 8089-8093, 2001.
6. Kolligs, F. T., et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell, 1: 145-155. 2001.
7. Jho, E. H., Zhang, T., Domon, C., Joo, C. K., Freund, J. N., and Costantini, F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol., 22: 1172-1183, 2001.
8. Yamada, T., Takaoka, A. S., Naishiro, Y., Hayashi, R., Maruyama, K., Maesawa, C., Ochiai, A., and Hirohashi, S. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/β-catenin complex in early colorectal carcinogenesis. Cancer Res., 60: 4761-4766, 2000.
9. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L., and Matrisian. L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA, 94: 1402-1407, 1997.
10. Roose, J., Huls, G., van Beest, M., Moerer, P., van der Horn, K., Goldschmeding, R., Logtenberg, T., and Clevers, H. Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science (Wash. DC), 285: 1923-1926, 1999.
11. Wilding, J., Straub, J., Bee, J., Churchman, M., Bodmer, W., Dickson, C., Tomlinson, I., and Ilyas, M. Cyclin D1 is not an essential target of β-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice. Cancer Res., 62: 4562-4565, 2002.
12. Su, L. K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gouldmm, K. A., and Dove, W. F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (Wash. DC), 256: 668-670, 1992.
13. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, CA., van der Valk. M. A., Robanus-Maandag, E. C., and te Riele, H. P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA, 94: 4028-4033, 1997.
14. Quaroni, A., Wands, J., Trelstad, R. L., and Isselbacher, K. J. Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J. Cell Biol., 80: 248-265, 1979.
15. Munemitsu, S., Albert, I., Rubinfeld, B., and Polakis, P. Deletion of an aminoterminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein. Mol. Cell. Biol., 16: 4088-4094, 1996.
16. Naishiro, Y., Yamada, T., Takaoka, A. S., Hayashi, R., Hasegawa, F., Imai. K., and Hirohashi, S. Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res., 61: 2751-2758, 2001.
17. Raymond, M., and Gros, P. Cell-specific activity of cis-acting regulatory elements in the promoter of the mouse multidrug resistance gene mdr1. Mol. Cell. Biol., 10: 6036-6040, 1990.
18. Hsu, S. I., Cohen, D., Kirschner, L. S., Lothstein, L., Hartstein, M., and Horwitz, S. B. Structural analysis of the mouse mdr1a (P-glycoprotein) promoter reveals the basis for differential transcript heterogeneity in mutidrug-resistant J774.2 cells. Mol. Cell. Biol., 10: 3596-3606, 1990.
19. MacPhee, M., Chepenik, K. P., Liddell, R. A., Nelson, K. K., Siracusa, L. D., and Buchberg, A. M. The secretory phospholipase A2 gene is a candidate for the Moml locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell, 81: 957-966, 1995.
20. Chan, T. A., Wang, Z., Dang, L. H., Vogelstein, B., and Kinzler, K. W. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc. Natl. Acad. Sci. USA, 99: 8265-8270, 2002.
21. Klein, I., Sarkadi, B., and Varadi, A. An inventory of the human ABC proteins. Biochim. Biophys. Acta Biochim. Biophys. Acta, 1461: 237-262, 1999.
22. Sonoshita, M, Takaku, K., Sasaki, N., Sugimoto, Y., Ushikubi, F., Narumiya, S., Oshima, M., and Taketo, M. M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med., 9: 1048-1051, 2001.
23. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1997.
24. Fantappie, O., Masini, E., Sardi, I., Raimondi, L., Bani, D., Solazzo, M., Vannacci, A., and Mazzanti, R. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology. 35: 843-852, 2002.
25. Patel, V. A., Dunn, M. J., and Sorokin, A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem., in press.
26. Raggers, R. J., Vogels, I., and van Meer, G. Upregulation of the expression of endogenous Mdr1 P-glycoprotein enhances lipid translocation in MDCK cells transfected with human MRP2. Biochem. J., 357: 859-865, 2002.
27. Soubeyran, P., Haglund, K., Garcia, S., Barth, B. U., Iovanna, J., and Dikic, I. Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells. Oncogene, 20: 4180-4187, 2001.
28. Kedinger, M., Simon-Assmann, P. M., Lacroix, B., Marxer, A., Hauri, H. P., and Haffen, K. Fetal gut mesenchyme induces differentiation of cultured intestinal endodermal and crypt cells. Dev. Biol., 113: 474-483, 1986.
29. Oshima, H., Oshima, M., Kobayashi, M., Tsutsumi, M., and Taketo, M. M. Morphological and molecular processes of polyp formation in Apc(Δ716) knockout mice. Cancer Res., 57: 1644-1649, 1997.
30. Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol., 40: S3-S8, 1997.
31. Thun, M. J., Henley, S. J., and Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. (Bethesda), 94: 252-266, 2002.
32. Naito, M., and Tsuruo, T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother. Pharmacol., 40: S20-S24, 1997.
33. Smit, J. W., Huisman, M. T, van Tellingen, O., Wiltshire, H. R., and Schinkel, A. H. Absence of pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin, Investig., 104: 1441-1447, 1999.